Ann: Kazia releases final data from P2 paxalisib trial, page-77

Anyone selling under $2 is doing so under duress, or is simply impatient and therefor not disposed to making money on the stock market outside of speculative bubbles or doesn't understand why they bought the shares in the first place. I couldn't imagine our board or many long term shareholders consider any offer that is not substantially north of $2 (by a multiple).

So far today we have seen 300K of shares traded. Meh.